Amanda Ganem, MD
Cardiovascular Disease · Rye, NYNPI 1841339702
Payments from drug & device makers
What this record shows
This record is dominated by education: $80 of the $108 with a category attached, or 74.4%. Astellas Pharma US Inc accounts for 74.4% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in NY, where the typical reported total is $1,486.
Across 2 payments — averaging $53.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$80
- Medtronic$28
What the payments were for
- Food & beverage$2826%
- Education$8074%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $80 |
| Medtronic | 1 | $28 |
How this compares
$108 in reported general payments places this provider in the 10th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 657 | $896,447 |
| EntrestoSacubitril/Valsartan | 140 | $202,409 |
| XareltoRivaroxaban | 125 | $161,896 |
| JardianceEmpagliflozin | 86 | $100,900 |
| Repatha SureclickEvolocumab | 24 | $31,100 |
| FarxigaDapagliflozin Propanediol | 20 | $29,239 |
| Metoprolol Succinate | 989 | $16,215 |
| Rosuvastatin Calcium | 582 | $9,939 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 207 | $9,105 |
| Atorvastatin Calcium | 583 | $7,272 |
| Ezetimibe | 227 | $6,669 |
| Carvedilol ErCarvedilol Phosphate | 11 | $6,112 |
| Clonidine | 25 | $4,747 |
| Valsartan | 128 | $4,716 |
| Verapamil SrVerapamil Hcl | 16 | $3,504 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Rye
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.